These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28689244)

  • 1. Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.
    Prakash NS; Lopategui DM; Gomez C
    Curr Urol Rep; 2017 Aug; 18(8):64. PubMed ID: 28689244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction.
    O'Connor RC; Johnson DP; Guralnick ML
    Neurourol Urodyn; 2020 Nov; 39(8):2322-2328. PubMed ID: 32866304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
    Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
    Krhut J; Samal V; Nemec D; Zvara P
    Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of toxin-A Botulinum for treating intractable bladder hyperactivity in children affected by neuropathic bladder secondary to myelomeningocele: an alternative to enterocystoplasty].
    Marte A; Vessella A; Cautiero P; Romano M; Borrelli M; Noviello C; Del Gado R; Parmeggiani P
    Minerva Pediatr; 2005 Feb; 57(1):35-40. PubMed ID: 15791200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of Botulinum-A toxin injection into bladder to treat neurogenic incontinence in patients with spinal cord injury: comparison of two doses].
    Fu G; Wu J; Cong H; Zha L; Li D; Ju Y; Chen G; Xiong Z; Liao L
    Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(48):3920-3. PubMed ID: 27122214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder.
    Chapple C
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S1. PubMed ID: 25042136
    [No Abstract]   [Full Text] [Related]  

  • 13. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of non-surgical management of detrusor leak point pressures above 40 cm water in adults with congenital neurogenic bladder.
    Lane GI; Gor RA; Katorski J; Elliott SP
    Neurourol Urodyn; 2018 Aug; 37(6):1943-1949. PubMed ID: 29488655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of botulinum toxin type A in paediatric neurogenic bladder management.
    Scheepe JR; Blok BF; 't Hoen LA
    Curr Opin Urol; 2017 Jan; 27(1):14-19. PubMed ID: 27748667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
    Chen SF; Chang CH; Kuo HC
    Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study.
    Conte A; Giannantoni A; Gubbiotti M; Pontecorvo S; Millefiorini E; Francia A; Porena M; Berardelli A
    Toxins (Basel); 2015 Aug; 7(9):3424-35. PubMed ID: 26343721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.